The CAR T-Cell Therapy Program at Smilow Cancer Hospital brings an innovative new immunotherapy treatment option to patients with certain blood cancers. Chimeric Antigen Receptor (CAR) T-cell therapy reprograms a patient’s own T-cells to target tumor antigens. CAR T-cell therapy has shown complete remission rates of 80 to 90 percent in younger patients with B-cell acute lymphoblastic leukemia, and 40 percent in patients with aggressive B-cell non-Hodgkin’s lymphomas who have failed multiple prior lines of treatment. The groundbreaking therapy is currently only available in Connecticut at Smilow Cancer Hospital.

The program’s Co-Directors are Stuart Seropian, MD, Associate Professor of Medicine, and Iris Isufi, MD, Assistant Professor of Medicine. Katrina Bezak, MS, APRN, is the Program Manager and available to assist with questions. At this time, the therapy is only FDA-approved for patients with childhood (up to age 25) acutelymphoblastic leukemia, the most common cancer in children, or adult B-cell non-Hodgkin’s lymphoma. However, researchers at Yale are conducting clinical trials to test new CAR T-cell therapies against other cancers, and Dr. Seropian and Dr. Isufi expect CAR T-cell therapies to be approved for a wider array of lymphomas and leukemias, and expanded to include all age groups.

For information please call (203) 200-CART